The Life Sciences team advised Rapport Therapeutics in the completion of its $150 million in Series B funding. Led by Cormorant Asset Management, the round includes investments from Fidelity Management & Research Company, Goldman Sachs Asset Management, Logos Capital, Perceptive Advisors, Sofinnova Investments, Surveyor Capital (a Citadel company), funds and accounts advised by T. Rowe Price Associates, Inc., and all existing investors, which include Third Rock Ventures, ARCH Venture Partners and Johnson & Johnson Innovation – JJDC, Inc.
The Goodwin team was led by Stephanie Richards, Sam Beavers and Kingsley Taft, and included Larissa Pinho, Frank Qin, Julie Tibbets and Matt Wetzel.
Rapport pursues precision neuromedicine in an effort to give patients better alternatives to current treatments for neurological diseases, which often come with reduced efficacy and side effects that lead to suboptimal dosing, noncompliance and discontinuation.
For additional details on the financing round, please read the press release and coverage in Endpoints and Boston Business Journal.
The Goodwin team was led by Stephanie Richards, Sam Beavers and Kingsley Taft, and included Larissa Pinho, Frank Qin, Julie Tibbets and Matt Wetzel.
Rapport pursues precision neuromedicine in an effort to give patients better alternatives to current treatments for neurological diseases, which often come with reduced efficacy and side effects that lead to suboptimal dosing, noncompliance and discontinuation.
For additional details on the financing round, please read the press release and coverage in Endpoints and Boston Business Journal.